BioCryst Pharmaceuticals (BCRX) Stock Overview
A biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
BCRX Community Fair Values
Create NarrativeSee what 40 others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
BioCryst Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.89 |
| 52 Week High | US$11.31 |
| 52 Week Low | US$6.00 |
| Beta | 0.69 |
| 1 Month Change | 13.03% |
| 3 Month Change | 33.65% |
| 1 Year Change | 54.29% |
| 3 Year Change | 17.60% |
| 5 Year Change | -12.79% |
| Change since IPO | 52.15% |
Recent News & Updates
Recent updates
BioCryst: The Buyout Rumor Is Noise, The Franchise Is Real
Mar 17Earnings Beat: BioCryst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 06
BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 07
ORLADEYO Pipeline Will Deliver New Therapeutic Opportunities
ORLADEYO's revenue growth, patient conversion, and reduced royalty payments enhance profitability, cash flow, and financial stability for BioCryst Pharmaceuticals.BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical
Feb 25BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Fly 25% But Investors Aren't Buying For Growth
Feb 15BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy
Dec 09BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade)
Sep 29Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results
Aug 08Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects
Jul 21Shareholder Returns
| BCRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 9.6% | 1.6% | 3.4% |
| 1Y | 54.3% | 46.8% | 29.7% |
Return vs Industry: BCRX exceeded the US Biotechs industry which returned 41.7% over the past year.
Return vs Market: BCRX exceeded the US Market which returned 25.7% over the past year.
Price Volatility
| BCRX volatility | |
|---|---|
| BCRX Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: BCRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BCRX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 435 | Charlie Gayer | www.biocryst.com |
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial.
BioCryst Pharmaceuticals, Inc. Fundamentals Summary
| BCRX fundamental statistics | |
|---|---|
| Market cap | US$2.45b |
| Earnings (TTM) | US$263.86m |
| Revenue (TTM) | US$874.84m |
Is BCRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCRX income statement (TTM) | |
|---|---|
| Revenue | US$874.84m |
| Cost of Revenue | US$183.16m |
| Gross Profit | US$691.68m |
| Other Expenses | US$427.82m |
| Earnings | US$263.86m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.05 |
| Gross Margin | 79.06% |
| Net Profit Margin | 30.16% |
| Debt/Equity Ratio | -390.8% |
How did BCRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/09 11:24 |
| End of Day Share Price | 2026/04/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioCryst Pharmaceuticals, Inc. is covered by 27 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |
| Steven Seedhouse | Cantor Fitzgerald & Co. |